Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
BSX is expected to have registered strong growth in the Asia Pacific, which is led by strength in China and Japan.
Boston Scientific (BSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Boston Scientific (BSX) reachead $86.20 at the closing of the latest trading day, reflecting a -0.58% change compared to its last close.
Here is how Boston Scientific (BSX) and Arcellx, Inc. (ACLX) have performed compared to their sector so far this year.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Royal Caribbean Cruises, Boston Scientific and Monolithic Power Systems have been selected as the top picks with a high net income ratio.
In the most recent trading session, Boston Scientific (BSX) closed at $84.54, indicating a +0.86% shift from the previous trading day.
Boston Scientific (BSX) closed at $84.49 in the latest trading session, marking a +0.42% move from the prior day.
Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive MedSurg market share gain.
Here, we pick three MedTech stocks, VCYT, BSX and PAHC, which are anticipated to gain strongly in 2024 from the loosening of monetary policy.